🇺🇸 FDA
Patent

US 8334373

Nuclease resistant double-stranded ribonucleic acid

granted A61PA61P43/00

Quick answer

US patent 8334373 (Nuclease resistant double-stranded ribonucleic acid) held by Alnylam Pharmaceuticals, Inc. expires Mon Dec 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Dec 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61P, A61P43/00